James Sapirstein, CEO of AzurRx BioPharma, Inc. talks about their biopharmaceutical products.

0
96

See the full episode at: https://newtothestreet.com/new-to-the-street-june-6th-digital-development-partners-azurrx-biopharma-tgi-solar-power-group-tamino-minerals-askvet-globex

The show interviews James Sapirstein, Chairman & CEO of AzurRx BioPharma, Inc. (NASDAQ: AZRX), talking about AZRX’s biopharmaceutical products and therapies. He gives a comprehensive overview in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. And, provides insight on its FDA Phase 2 clinical trials on its lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.

To make sure you never miss a video from New to the Street, click here to subscribe: https://www.youtube.com/channel/UCceRKKS0QUfXlKUPBoxdTHQ

Follow New to the Street on Twitter: https://twitter.com/NewToTheStreet
Follow New to the Street on Facebook: https://www.facebook.com/newtothestreet/
Follow New to the Street on Instagram: https://www.instagram.com/newtothestreettv/

Subscribe to our Mailing List: https://mailchi.mp/ccd21b3e3fab/join-our-mailing-list